[CAS NO. 70-00-8] Trifluridine (NSC 75520)

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [70-00-8]

Catalog

SLK-S1778

Brand

Selleck

CAS

70-00-8

DESCRIPTION [70-00-8]

Overview

MDL	MFCD00006534
Molecular Weight	296.2
Molecular Formula	C10H11F3N2O5
SMILES	O=C1N([C@@]2(O[C@H](CO)[C@@H](O)C2)[H])C=C(C(F)(F)F)C(=O)N1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	3.3761 mL	16.8805 mL	33.7610 mL
5 mM	0.6752 mL	3.3761 mL	6.7522 mL
10 mM	0.3376 mL	1.6880 mL	3.3761 mL
50 mM	0.0675 mL	0.3376 mL	0.6752 mL

Description

Trifluridine (NSC 529182, NSC 75520, Viroptic, Trifluorothymidine, TFT) is an anti-herpesvirus antiviral agent by interacting viral DNA replication, used primarily on the eye.

Targets

DNA synthesis ^[1]

In vitro

Trifluridine inhibits proliferations of mouse bone marrow cells and human colorectal carcinoma cells implanted to nude mice dose-dependently. Trifluridine inhibits colony formation of bone marrow cells in a concentration-dependent manner. Trifluridine (FTD) and 2'-deoxy-5-fluorouridine (FdUrd) are incorporated into DNA with different efficiencies due to differences in the substrate specificities of TK1 and DUT, causing abundant FTD incorporation into DNA. FTD-treated cells shows differing nuclear morphologies compared to FdUrd-treated cells. Trifluridine inhibits proliferations of mouse bone marrow cells and human colorectal carcinoma cells implanted to nude mice dose-dependently.

In vivo

Trifluridine has significantly fewer swabs positive for HSV-1 than the untreated eyes in the infected rabbits. Trifluridine has increased antitumor activity and is incorporated into DNA more effectively than continuously infused Trifluridine in mice. Trifluridine gradually accumulates in tumor cell DNA, in a TPI-independent manner, and significantly delays tumor growth and prolonged survival in mice, compared to treatment with 5-FU derivatives. Trifluridine results in significantly lower viral titers, fewer HSV-1-positive eyes/total during the treatment period, lower keratitis scores, fewer eyes with keratitis/total, and a shorter time to resolution of keratitis in the New Zealand rabbit ocular model.

References

[1] Yamashita F, et al. Cancer Chemother Pharmacol,?015 Jun 18.
[2] Sakamoto K, et al. Int J Oncol,?015, 46(6), 2327-2334.
[3] Germano A, et al. Mol燙ell燛ndocrinol,?014, 382(1), 1-7.
[4] Rootman DS, et al. Invest Ophthalmol Vis Sci,?989, 30(4), 678-683.
[5] Tanaka N, et al. Oncol Rep,?014, 32(6), 2319-2326.
[6] Romanowski EG, et al. Invest Ophthalmol Vis Sci,?999, 40(2), 378-384.

Synonyms

Thymidine, α,α,α-trifluoro-

Uridine, 2′-deoxy-5-(trifluoromethyl)-

α,α,α-Trifluorothymidine

5-(Trifluoromethyl)-2′-deoxyuridine

Trifluorothymidine

2′-Deoxy-5-(trifluoromethyl)uridine

5-(Trifluoromethyl)deoxyuridine

Trifluridine

Viroptic

5-Trifluoromethyl-2′-deoxy-β-uridine

5-Trifluorothymidine

NSC 529182

NSC 75520